Skip to main content

Table 1 Number and proportion (%) of nalidixic acid-, ciprofloxacin- and multidrug-resistant Salmonella Typhi isolated between 2002 and 2013

From: Antimicrobial susceptibility of travel-related Salmonella enterica serovar Typhi isolates detected in Switzerland (2002–2013) and molecular characterization of quinolone resistant isolates

   Resistance pattern
Total no. of isolates   NAL CIP MDRa
  Year no. (%) no. (%) no. (%)
10 2002 2 (20) 0 (0) 0 (0)
16 2003 6 (37.5) 0 (0) 2 (12.5)
13 2004 5 (38.5) 1 (7.7) 2 (15.4)
16 2005 5 (31.3) 3 (18.8) 1 (6.3)
16 2006 9 (56.3) 3 (18.8) 0 (0)
18 2007 15 (83.3) 5 (27.8) 3 (16.7)
16 2008 9 (56.3) 3 (18.8) 3 (18.8)
18 2009 14 (77.8) 1 (5.6) 1 (5.6)
24 2010 20 (83.3) 6 (25) 4 (16.7)
15 2011 9 (60) 4 (26.7) 3 (20)
12 2012 7 (58.3) 3 (25) 3 (25)
18 2013 12 (66.7) 10 (55.6) 0 (0)
Total     
192   113 (58.9) 39 (20.3) 22 (11.5)
  1. Abbreviations: NAL, nalidixic acid; CIP, ciprofloxacin; MDR, multidrug resistant
  2. aMultidrug resistance is defined as resistance to ampicillin, trimethoprim/sulfamethoxazole and chloramphenicol (13)
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us